In this “Meet the Editors” highlight, we feature Nikla Emambokus, PhD, Executive Editor at Cell Press, and the Editor-in-Chief of Cell Press’s new flagship clinical and translational journal, Med.
In this new role, she is responsible for shaping and directing what Med publishes and its impact on science and society, and will be looking for groundbreaking stories to highlight in the new journal at the upcoming “Advances in Cancer Immunotherapy” meeting in Whistler, Canada.
Follow up-to-the-minute coverage of the “Advances in Cancer Immunotherapy” meeting on Twitter:
Why are you attending this conference? What do you hope to get out of it?
Dr. Nikla Emambokus: Cancer Immunotherapy is an extremely exciting area of research, with tangible implications for patient care. There are however also important challenges.
Our new journal Med has a strong focus on publishing carefully-vetted research with therapeutic impact.
I am looking forward to attending the Keystone Symposia on Advances in Cancer Immunotherapy in Whistler, Canada to catch up on where the field is at currently, where it is heading next and connecting with the researchers.
What do you enjoy most about attending Keystone Symposia conferences?
Dr. Nikla Emambokus: Keystone Symposia are some of the best at capturing exciting and timely scientific themes with outstanding speakers at the forefront of the field of research. They are also almost invariably held in spectacular locations that most of us would not normally go to. No matter how many Keystone conferences I attend, I especially enjoy the animated scientific discussions at the poster sessions.
In recent years, I have appreciated the commitment of Keystone Symposia to host conferences in different regions of the world and their push to promote gender diversity and the representation of early-career stage scientists.
What’s the best way for attendees to get in touch with you at the meeting?
What are the exciting things happening at your journal right now?
Dr. Nikla Emambokus: With Med, we have the chance to build something new from the ground up and address many of the unique challenges of translational science, including rigor and reproducibility, ethics and sustainability.
Besides clinical researchers and translational scientists from across the world, our vision is to bring biotech/pharma and health policy experts to Med’s fold.
CAREER INSIGHTS– What motivated you to choose a career in science publishing and editing?
Dr. Nikla Emambokus: Scientific publishing and editing had been a bit of a calling early on in my scientific career. Nature was, and is, a constant source of inspiration for the breadth of the research that they publish. I wanted to be connected to cutting-edge science in the broadest terms and had the opportunity to join Cell Press over a decade ago. I have been extremely lucky to be exposed to some of the best life- and physical-sciences that we publish and am very much looking forward to bringing the best in medicine to our readers.
About the Author:
Nikla Emambokus, PhD– Editor-in-Chief, Med (Cell Press)
Nikla comes from a ten-year tenure as Editor-in-Chief at Cell Metabolism, where she diversified and expanded the scope of the journal to include clinical and translational work. Prior to joining Cell Press, Nikla received her PhD in biochemistry and molecular medicine from the University of Oxford. She then did her postdoctoral research at the Weatherall Institute of Molecular Medicine in Oxford and Boston Children’s Hospital | Harvard Medical School focusing on the molecular determinants of blood stem and progenitor cells in the mouse. Besides her passion for rigorous and impactful clinical and translational research, Nikla’s vision for Med is to bring together research scientists across the translational spectrum, including biotech, pharma, regulatory, and policy experts. Her goal is to champion new ideas and strategies that will ethically and sustainably accelerate closing the bench-to-bedside gap and improve lives.
See More Editor Insights from the New Cell Press Journal “Med” on the Keypoint Blog: